| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE:ABBV).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ABBV, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 13 uncommon options trades for AbbVie.
This isn't normal.
The overall sentiment of these big-money traders is split between 69% bullish and 30%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $431,615, and 8 are calls, for a total amount of $725,750.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $170.0 to $225.0 for AbbVie over the last 3 months.
In today's trading context, the average open interest for options of AbbVie stands at 1766.69, with a total volume reaching 3,346.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in AbbVie, situated within the strike price corridor from $170.0 to $225.0, throughout the last 30 days.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | CALL | SWEEP | BULLISH | 01/16/26 | $30.45 | $27.35 | $29.34 | $190.00 | $233.4K | 1.6K | 0 |
| ABBV | CALL | TRADE | BEARISH | 12/05/25 | $2.69 | $1.9 | $2.21 | $225.00 | $213.2K | 24 | 969 |
| ABBV | PUT | SWEEP | BULLISH | 11/07/25 | $1.71 | $1.42 | $1.42 | $212.50 | $211.1K | 99 | 1.7K |
| ABBV | CALL | TRADE | BEARISH | 02/20/26 | $10.1 | $10.0 | $10.0 | $220.00 | $100.0K | 1.0K | 103 |
| ABBV | PUT | SWEEP | BEARISH | 11/21/25 | $3.75 | $3.55 | $3.75 | $212.50 | $92.2K | 267 | 257 |
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Following our analysis of the options activities associated with AbbVie, we pivot to a closer look at the company's own performance.
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $259.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * An analyst from Piper Sandler persists with their Overweight rating on AbbVie, maintaining a target price of $284. * An analyst from Raymond James downgraded its action to Outperform with a price target of $250. * Consistent in their evaluation, an analyst from Guggenheim keeps a Buy rating on AbbVie with a target price of $242. * An analyst from JP Morgan has decided to maintain their Overweight rating on AbbVie, which currently sits at a price target of $260.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with Benzinga Pro for real-time alerts.
Posted In: ABBV
